1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
61700919338D34E348525823A0070832C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-in-Improving-medical-affairs-booth-impact-at-congresses-content-type-availability-and-display-methods?opendocument
18
19opendocument
2018.205.176.85
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Communication

Best Practices in Improving Medical Affairs Booth Impact at Congresses: Content Type, Availability and Display Methods

ID: 5499


Features:

16 Info Graphics

14 Data Graphics

600+ Metrics

4 Narratives


Pages/Slides: 35


Published: 2018


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Best Practices in Improving Medical Affairs Booth Impact at Congresses: Content Type, Availability and Display Methods"

STUDY OVERVIEW


An engaging medical booth presence at annual conferences such as ASH or ASCO is a key way to raise awareness and educate healthcare professionals about a pharmaceutical company's pipeline and products. However, new technologies and a conservative compliance mindset have made it challenging for some medical communications leaders to showcase their company's pipeline and products to thought leaders attending these medical congresses.

Best Practices, LLC performed this
research study to identify the types of medical content and display methods that are most effective for engaging thought leaders and other HCPs attending congresses. The study also examines whether companies are presenting medical information such as pipeline and disease state information in a proactive (without being asked) or reactive (only on request) manner.


This study will allow pharma leaders who oversee or are involved with medical booth displays at congresses to compare their booth display approach with peer organizations.

This study contains segments for Hematology/Oncology and Non-Hematology/Oncology as well as Large and Small Companies.

KEY TOPICS

  • Benchmark Participant Demographics
  • Booth Content
  • Booth Display Methods

SAMPLE KEY METRICS

  • What types of content are you displaying in your medical congress booth and how is it shared?
  • What are the most important factors affecting your company's decision on which types of content to display?

SAMPLE KEY FINDING


  • HemOnc-Oriented Booths use More Types of Display Methods than Other TAs: At least 50% of the HemOnc Segment use more than one type of display method for 13 of the 17 content types evaluated. Meanwhile, at least 50% of the Non-HemOnc Segment use more than one type of display method for 6 of 17 content types.
  • A majority of the HemOnc Segment use Static Panels, Handouts, Interactive and iPads to display Pipeline, Clinical Trial, and Disease State information.
  • Both segments prefer to use Handouts and iPads to share content proactively as well as reactively.
  • For the HemOnc Segment, iPads are the go-to display method for key content (Pipeline, Clinical Trial, MoD Pipeline, Disease State).

METHODOLOGY


Best Practices, LLC engaged 21 Medical Affairs leaders at 20 pharmaceutical companies for this research project. In addition to utilizing a survey to collect quantitative data, the study included four executive interviews to collect qualitative data.


Industries Profiled:
Biotech; Pharmaceutical; Manufacturing; Chemical; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Allergan; amag; Amgen; AstraZeneca; Biogen; Boehringer Ingelheim; Celgene; Exelixis ; Ferring Pharmaceuticals; LifeScan; Indivior; Merck; Genentech; Novartis; Pfizer; Sanofi; Sunovion; TG Therapeutics; Tillotts Pharma; Takeda Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.